Holley
Holley v. Gilead Sciences, Inc.
Opinion
Trial Court Opinion
UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA 6 ADRIAN HOLLEY, et al., Case No. 18-cv-06972-JST
Plaintiffs,
ORDER GRANTING IN PART AND
v. DENYING IN PART DEFENDANT’S
MOTION FOR SUMMARY
GILEAD SCIENCES, INC., JUDGMENT ON COMMON ISSUES Defendant. Re: ECF No. 1126
12 Before the Court is Defendant Gilead Sciences, Inc.’s motion for summary judgment on common issues. ECF No. 1126. The Court will grant the motion in part and deny it in part. I. BACKGROUND Plaintiffs in these cases have taken one of more of Gilead’s drugs containing tenofovir disoproxil fumarate (“TDF”): Viread, Truvada, Atripla, Complera, and Stribild. The Court has consolidated approximately 75 cases for pretrial purposes only, with over 3,000 remaining plaintiffs from the District of Columbia and every state except for California and Delaware.1 Plaintiffs contend that they have suffered unnecessary kidney and bone damage caused by Gilead’s failure to provide adequate warnings…